Vantage Consulting Group’s Regenxbio RGNX Stock Holding History

Vantage Consulting Group’s Portfolio RGNX Stock Details RGNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-1,652	Closed	-$75K	–	1236
2020 Q4	$75K	Buy	+1,652	New	+$57.7K	0.01%	278

Other funds holding RGNX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

ACM

Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Vantage Consulting Group's RGNX Position: Q1 2021 in Review

Vantage Consulting Group sold out of Regenxbio (RGNX) in Q1 2021, closing a stake of 1,652 shares — an estimated $75K sold.

Vantage Consulting Group first reported a position in RGNX in Q4 2020 and held it in 1 quarter. The position peaked at $75K in Q4 2020. 184 funds tracked by Wall St. Rank hold RGNX as of Q1 2021.

Vantage Consulting Group reported no remaining Regenxbio position as of Q1 2021 after selling out during the quarter.
Vantage Consulting Group sold 1,652 Regenxbio shares in Q1 2021, an estimated $75K.
Vantage Consulting Group first reported a position in Regenxbio in Q4 2020 and held it in 1 quarter.
Vantage Consulting Group's Regenxbio position peaked at $75K in Q4 2020.
184 funds tracked by Wall St. Rank held Regenxbio as of Q1 2021.

Based on Vantage Consulting Group's 13F filing for Q1 2021, filed 14 May 2021.